Skip to main content
Top
Published in: BMC Infectious Diseases 1/2008

Open Access 01-12-2008 | Research article

Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting

Authors: Motasim Badri, Stephen D Lawn, Robin Wood

Published in: BMC Infectious Diseases | Issue 1/2008

Login to get access

Abstract

Background

Viral load monitoring is not available for the vast majority of patients receiving antiretroviral therapy in resource-limited settings. However, the practical utility of CD4 cell count measurements as an alternative monitoring strategy has not been rigorously assessed.

Methods

In this study, we used a novel modelling approach that accounted for all CD4 cell count and VL values measured during follow-up from the first date that VL suppression was achieved. We determined the associations between CD4 counts (absolute values and changes during ART), VL measurements and risk of virological failure (VL > 1,000 copies/ml) following initial VL suppression in 330 patients in South Africa. CD4 count changes were modelled both as the difference from baseline (ΔCD4 count) and the difference between consecutive values (CD4 count slope) using all 3-monthly CD4 count measurements during follow-up.

Results

During 7093.2 patient-months of observation 3756 paired CD4 count and VL measurements were made. In patients who developed virological failure (n = 179), VL correlated significantly with absolute CD4 counts (r = - 0.08, P = 0.003), ΔCD4 counts (r = - 0.11, P < 0.01), and most strongly with CD4 count slopes (r = - 0.30, P < 0.001). However, the distributions of the absolute CD4 counts, ΔCD4 counts and CD4 count slopes at the time of virological failure did not differ significantly from the corresponding distributions in those without virological failure (P = 0.99, P = 0.92 and P = 0.75, respectively). Moreover, in a receiver operating characteristic (ROC) curve, the association between a negative CD4 count slope and virological failure was poor (area under the curve = 0.59; sensitivity = 53.0%; specificity = 63.6%; positive predictive value = 10.9%).

Conclusion

CD4 count changes correlated significantly with VL at group level but had very limited utility in identifying virological failure in individual patients. CD4 count is an inadequate alternative to VL measurement for early detection of virological failure.
Appendix
Available only for authorised users
Literature
3.
go back to reference Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, Platt RW, Wood R, Beck EJ: Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med. 2006, 1: e4-10.1371/journal.pmed.0030004. Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, Platt RW, Wood R, Beck EJ: Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med. 2006, 1: e4-10.1371/journal.pmed.0030004.
4.
go back to reference Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R: When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther. 2006, 11: 63-72.PubMed Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R: When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther. 2006, 11: 63-72.PubMed
6.
go back to reference Colebunders R, Moses KR, Laurence J, Shihab HM, Semitala F, Lutwama F, Bakeera-Kitaka S, Lynen L, Spacek L, Reynolds SJ, Quinn TC, Viner B, Mayanja-Kizza H: A new model to monitor the virological efficacy of antiretroviral treatment in resource poor countries. Lancet Infect Dis. 2006, 6: 53-59. 10.1016/S1473-3099(05)70327-3.CrossRefPubMed Colebunders R, Moses KR, Laurence J, Shihab HM, Semitala F, Lutwama F, Bakeera-Kitaka S, Lynen L, Spacek L, Reynolds SJ, Quinn TC, Viner B, Mayanja-Kizza H: A new model to monitor the virological efficacy of antiretroviral treatment in resource poor countries. Lancet Infect Dis. 2006, 6: 53-59. 10.1016/S1473-3099(05)70327-3.CrossRefPubMed
7.
go back to reference Lawn SD, Orrell C, Wood R: Evaluating a model for monitoring the virological efficacy of antiretroviral treatment in resource-limited settings. Lancet Infect Dis. 2006, 7: 385-386. 10.1016/S1473-3099(06)70498-4.CrossRef Lawn SD, Orrell C, Wood R: Evaluating a model for monitoring the virological efficacy of antiretroviral treatment in resource-limited settings. Lancet Infect Dis. 2006, 7: 385-386. 10.1016/S1473-3099(06)70498-4.CrossRef
8.
go back to reference Rodríguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, Boswell SL, Mathews WC, Bangsberg DR, Martin J, Whalen CC, Sieg S, Yadavalli S, Deeks SG, Lederman MM: Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006, 296: 1498-506. 10.1001/jama.296.12.1498.CrossRefPubMed Rodríguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, Boswell SL, Mathews WC, Bangsberg DR, Martin J, Whalen CC, Sieg S, Yadavalli S, Deeks SG, Lederman MM: Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006, 296: 1498-506. 10.1001/jama.296.12.1498.CrossRefPubMed
9.
go back to reference Henry WK, Tebas P, Lane HC: Explaining, predicting, and treating HIV-associated CD4 cell loss. After 25 years still a puzzle. JAMA. 2006, 296: 1523-5. 10.1001/jama.296.12.1523.CrossRefPubMed Henry WK, Tebas P, Lane HC: Explaining, predicting, and treating HIV-associated CD4 cell loss. After 25 years still a puzzle. JAMA. 2006, 296: 1523-5. 10.1001/jama.296.12.1523.CrossRefPubMed
10.
go back to reference Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L: Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000, 133: 401-410.CrossRefPubMed Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L: Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000, 133: 401-410.CrossRefPubMed
11.
go back to reference Piketty C, Castiel P, Belec L, Batisse D, Si Mohamed A, Gilquin J, Gonzalez-Canali G, Jayle D, Karmochkine M, Weiss L, Aboulker JP, Kazatchkine MD: Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998, 12: 745-750. 10.1097/00002030-199807000-00011.CrossRefPubMed Piketty C, Castiel P, Belec L, Batisse D, Si Mohamed A, Gilquin J, Gonzalez-Canali G, Jayle D, Karmochkine M, Weiss L, Aboulker JP, Kazatchkine MD: Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998, 12: 745-750. 10.1097/00002030-199807000-00011.CrossRefPubMed
12.
go back to reference Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A, EuroSIDA Study Group: Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSida study. HIV Med. 2003, 4: 255-262. 10.1046/j.1468-1293.2003.00156.x.CrossRefPubMed Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A, EuroSIDA Study Group: Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSida study. HIV Med. 2003, 4: 255-262. 10.1046/j.1468-1293.2003.00156.x.CrossRefPubMed
13.
go back to reference Pakker NG, Kroon ED, Roos MT, Otto SA, Hall D, Wit FW, Hamann D, Ende van der ME, Claessen FA, Kauffmann RH, Koopmans PP, Kroon FP, ten Napel CH, Sprenger HG, Weigel HM, Montaner JS, Lange JM, Reiss P, Schellekens PT, Miedema F: Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS. 1999, 13: 203-212. 10.1097/00002030-199902040-00008.CrossRefPubMed Pakker NG, Kroon ED, Roos MT, Otto SA, Hall D, Wit FW, Hamann D, Ende van der ME, Claessen FA, Kauffmann RH, Koopmans PP, Kroon FP, ten Napel CH, Sprenger HG, Weigel HM, Montaner JS, Lange JM, Reiss P, Schellekens PT, Miedema F: Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS. 1999, 13: 203-212. 10.1097/00002030-199902040-00008.CrossRefPubMed
14.
go back to reference Jevtovic D, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O: The dissociation between virologic and immunologic responses to HAART. Biomed Pharmacother. 2005, 59: 446-451. 10.1016/j.biopha.2005.07.006.CrossRefPubMed Jevtovic D, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O: The dissociation between virologic and immunologic responses to HAART. Biomed Pharmacother. 2005, 59: 446-451. 10.1016/j.biopha.2005.07.006.CrossRefPubMed
15.
go back to reference Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom BL, Gaolathe T, Ndwapi N: Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS. 2006, 20: 1613-1619.CrossRefPubMed Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom BL, Gaolathe T, Ndwapi N: Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS. 2006, 20: 1613-1619.CrossRefPubMed
16.
go back to reference Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med. 2000, 160: 1123-1132. 10.1001/archinte.160.8.1123.CrossRefPubMed Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med. 2000, 160: 1123-1132. 10.1001/archinte.160.8.1123.CrossRefPubMed
17.
go back to reference Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel FD, Phillips AN, Clotet B, Lundgren JD, EuroSIDA study group: Virological rebound after suppression on highly active antiretroviral therapy. AIDS. 2003, 17: 1741-1751. 10.1097/00002030-200308150-00003.CrossRefPubMed Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel FD, Phillips AN, Clotet B, Lundgren JD, EuroSIDA study group: Virological rebound after suppression on highly active antiretroviral therapy. AIDS. 2003, 17: 1741-1751. 10.1097/00002030-200308150-00003.CrossRefPubMed
18.
go back to reference Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S: Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses. 1999, 15: 1631-1638. 10.1089/088922299309676.CrossRefPubMed Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S: Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses. 1999, 15: 1631-1638. 10.1089/088922299309676.CrossRefPubMed
19.
go back to reference Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, Berlureau P, Dupont C, Fabbro-Peray P, Poizot-Martin I, Costagliola D: Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000, 14: 141-149. 10.1097/00002030-200001280-00009.CrossRefPubMed Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, Berlureau P, Dupont C, Fabbro-Peray P, Poizot-Martin I, Costagliola D: Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000, 14: 141-149. 10.1097/00002030-200001280-00009.CrossRefPubMed
20.
go back to reference Fournier S, Chaffaut C, Maillard A, Loze B, Lascoux C, Gérard L, Timsit J, David F, Bergmann JF, Oksenhendler E, Sereni D, Chevret S, Molina JM: Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study. HIV Med. 2005, 6: 129-134. 10.1111/j.1468-1293.2005.00275.x.CrossRefPubMed Fournier S, Chaffaut C, Maillard A, Loze B, Lascoux C, Gérard L, Timsit J, David F, Bergmann JF, Oksenhendler E, Sereni D, Chevret S, Molina JM: Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study. HIV Med. 2005, 6: 129-134. 10.1111/j.1468-1293.2005.00275.x.CrossRefPubMed
21.
go back to reference Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M: Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr. 2005, 40: 324-328. 10.1097/01.qai.0000182627.28595.01.CrossRefPubMed Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M: Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr. 2005, 40: 324-328. 10.1097/01.qai.0000182627.28595.01.CrossRefPubMed
22.
go back to reference Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouzé B, Verdon R: Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004, 38: 1311-1316. 10.1086/383572.CrossRefPubMed Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouzé B, Verdon R: Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004, 38: 1311-1316. 10.1086/383572.CrossRefPubMed
23.
go back to reference Le Moing V, Chêne G, Carrieri MP, Alioum A, Brun-Vézinet F, Piroth L, Cassuto JP, Moatti JP, Raffi F, Leport C, Aproco Study Group: Predictors of virological rebound in HIV-1 infected patients initiating a protease-containing regimen. AIDS. 2002, 16: 21-29. 10.1097/00002030-200201040-00004.CrossRefPubMed Le Moing V, Chêne G, Carrieri MP, Alioum A, Brun-Vézinet F, Piroth L, Cassuto JP, Moatti JP, Raffi F, Leport C, Aproco Study Group: Predictors of virological rebound in HIV-1 infected patients initiating a protease-containing regimen. AIDS. 2002, 16: 21-29. 10.1097/00002030-200201040-00004.CrossRefPubMed
24.
go back to reference Badri M, Wilson D, Wood R: Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002, 359: 2059-2064. 10.1016/S0140-6736(02)08904-3.CrossRefPubMed Badri M, Wilson D, Wood R: Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002, 359: 2059-2064. 10.1016/S0140-6736(02)08904-3.CrossRefPubMed
25.
go back to reference Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, Wood R: Conservation of first line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007, 12: 83-88.PubMed Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, Wood R: Conservation of first line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007, 12: 83-88.PubMed
26.
go back to reference Balakrishnan P, Solomon S, Kumarasamy N, Mayer KH: Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. Indian J Med Res. 2005, 121: 345-355.PubMed Balakrishnan P, Solomon S, Kumarasamy N, Mayer KH: Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. Indian J Med Res. 2005, 121: 345-355.PubMed
Metadata
Title
Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting
Authors
Motasim Badri
Stephen D Lawn
Robin Wood
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2008
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-8-89

Other articles of this Issue 1/2008

BMC Infectious Diseases 1/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.